RAM
GALT icon

Riggs Asset Management’s Galectin Therapeutics GALT Stock Holding History

Riggs Asset Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,000
Closed -$5K – 256
2018
Q1 		$5K Hold
1,000
– – ﹤0.01% 224
2017
Q4 		$3K Hold
1,000
– – ﹤0.01% 239
2017
Q3 		$2K Hold
1,000
– – ﹤0.01% 246
2017
Q2 		$2K Hold
1,000
– – ﹤0.01% 268
2017
Q1 		$2K Buy
+1,000
New +$1.51K ﹤0.01% 246

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EGI
EAM Global Investors Solana Beach, California $47.1M AUM 320.45% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Riggs Asset Management's GALT Position: Q2 2018 in Review

Riggs Asset Management sold out of Galectin Therapeutics (GALT) in Q2 2018, closing a stake of 1,000 shares — an estimated $5K sold.

Riggs Asset Management first reported a position in GALT in Q1 2017 and held it in 5 quarters. The position peaked at $5K in Q1 2018. 69 funds tracked by Wall St. Rank hold GALT as of Q2 2018.

  • Riggs Asset Management reported no remaining Galectin Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Riggs Asset Management sold 1,000 Galectin Therapeutics shares in Q2 2018, an estimated $5K.
  • Riggs Asset Management first reported a position in Galectin Therapeutics in Q1 2017 and held it in 5 quarters.
  • Riggs Asset Management's Galectin Therapeutics position peaked at $5K in Q1 2018.
  • 69 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2018.

Based on Riggs Asset Management's 13F filing for Q2 2018, filed 27 Jul 2018.